GRI Bio, Inc.
GRI
$1.51
-$0.02-1.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -45.23% | -50.79% | -40.27% | 201.94% | 308.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 100.00% | -- | -- | -- |
| Total Operating Expenses | -26.05% | -22.92% | -4.65% | 297.49% | 397.19% |
| Operating Income | 26.05% | 22.92% | 4.65% | -297.49% | -397.19% |
| Income Before Tax | 7.44% | 37.87% | 28.12% | -152.20% | -305.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 7.44% | 37.87% | 28.12% | -152.20% | -305.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.44% | 37.87% | 28.12% | -152.20% | -305.38% |
| EBIT | 26.05% | 22.92% | 4.65% | -297.49% | -397.19% |
| EBITDA | 26.06% | 22.93% | 4.65% | -297.75% | -397.68% |
| EPS Basic | 57.20% | 36.84% | -5.87% | -52.90% | -138.02% |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | 55.55% | 36.84% | -5.87% | -52.90% | -138.02% |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 897.93% | 255.05% | 20.83% | 12.14% | 15.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |